<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876328</url>
  </required_header>
  <id_info>
    <org_study_id>C15-33</org_study_id>
    <secondary_id>PREVACEBL3005</secondary_id>
    <nct_id>NCT02876328</nct_id>
  </id_info>
  <brief_title>Partnership for Research on Ebola VACcinations</brief_title>
  <acronym>PREVAC</acronym>
  <official_title>Partnership for Research on Ebola VACcinations (PREVAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Partnership for Research on Ebola Virus in Liberia (PREVAIL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of three vaccine
      strategies that may prevent Ebola virus disease (EVD) events in children and adults.
      Participants will receive either the Ad26.ZEBOV (rHAd26) vaccine with a MVA-BN-Filo (MVA)
      boost, or the rVSVΔG-ZEBOV-GP (rVSV) vaccine with or without boosting, or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of two Ebola virus
      disease (EVD) vaccines, Ad26.ZEBOV (rHAd26) and rVSVΔG-ZEBOV-GP (rVSV), in children and
      adults. These vaccines will be studied using three different strategies: the rHAd26 vaccine
      plus a MVA-BN-Filo (MVA) boost, and the rVSV vaccine with or without boosting.

      Participants will be randomized into five groups: the Ad26.ZEBOV vaccine with an MVA boost,
      the rVSV vaccine with or without boosting, or one of two placebo groups. At Day 0 (study
      entry), participants will receive the Ad26.ZEBOV vaccine, the rVSV vaccine, or placebo.

      At Day 56, participants assigned to the rVSV vaccine without a boost and the two placebo
      groups will receive placebo. Those initially given the Ad26.ZEBOV vaccine will receive the
      MVA boost. Those assigned to the boosted rVSV group will receive the rVSV boost.

      Additional study visits will occur on Days 7, 14, 28, and 63, and at Months 3, 6, 12, 24, 36,
      48, and 60. Study visits may include blood collection and other assessments.

      Some participants may take part in substudies, which will include blood or saliva collection.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 31, 2017</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Ebola virus glycoprotein (GP-EBOV) antibody response</measure>
    <time_frame>Measured through Month 12</time_frame>
    <description>Antibodies to the Ebola virus glycoprotein will be measured with the Filovirus Animal Nonclinical Group (FANG) ELISA assay if available. Other assays may also be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of serious adverse events (SAEs)</measure>
    <time_frame>Measured through Month 60</time_frame>
    <description>SAEs as defined in the protocol</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">4789</enrollment>
  <condition>Ebola Virus Disease</condition>
  <arm_group>
    <arm_group_label>Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the Ad26.ZEBOV (rHAd26) vaccine at Day 0 followed by an MVA-BN-Filo (MVA) boost at Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (0.5 mL)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by a placebo boost at Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by an rVSV boost at Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (1 mL)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.ZEBOV</intervention_name>
    <description>0.5 mL at a dose of 5x10^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost</arm_group_label>
    <other_name>rHAd26</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-Filo</intervention_name>
    <description>0.5 mL at a dose of 1x10^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost</arm_group_label>
    <other_name>MVA</other_name>
    <other_name>MVA-mBN226B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rVSVΔG-ZEBOV-GP</intervention_name>
    <description>1 mL at a nominal dose of 2x10^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost</arm_group_label>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost</arm_group_label>
    <other_name>rVSV</other_name>
    <other_name>V920</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>Placebo (0.5 mL)</arm_group_label>
    <arm_group_label>Placebo (1 mL)</arm_group_label>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rVSV boost</intervention_name>
    <description>1 mL at a nominal dose of 2x10^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost</arm_group_label>
    <other_name>rVSVΔG-ZEBOV-GP</other_name>
    <other_name>rVSV</other_name>
    <other_name>V920</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent/assent

          -  Age greater than or equal to 1 year

          -  Planned residency in the area of the study site for the next 12 months

          -  Willingness to comply with the protocol requirements

        Exclusion Criteria:

          -  Fever greater than 38º Celsius

          -  History of EVD (self-report)

          -  Pregnancy (a negative urine pregnancy test is required for females of child-bearing
             potential, i.e., females who have experienced menarche or who are aged 14 years and
             older)

          -  Positive HIV test for participants less than 18 years of age

          -  Reported current breast-feeding

          -  Prior vaccination against Ebola (self-report)

          -  Any vaccination in the past 28 days or planned within the 28 days after randomization
             (initial vaccination)

          -  In the judgement of the clinician, any clinically significant acute/chronic condition
             that would limit the ability of the participant to meet the requirements of the study
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yazdan Yazdanpannah</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdoul Habib Beavogui</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Formation et de Recherche en Santé Rurale de Mafèrinyah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Kieh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Redemption Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bailah Leigh</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sierra Leone</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre national de formation et de recherche en santé rurale (Maferyniah)</name>
      <address>
        <city>Conakry</city>
        <country>Guinea</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landreah</name>
      <address>
        <city>Conakry</city>
        <country>Guinea</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Redemption Hospital</name>
      <address>
        <city>Monrovia</city>
        <country>Liberia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre pour le Développement des Vaccins (CVD)</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research Center (UCRC)</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mambolo Clinic</name>
      <address>
        <city>Kapesseh</city>
        <country>Sierra Leone</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guinea</country>
    <country>Liberia</country>
    <country>Mali</country>
    <country>Sierra Leone</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ebola Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02876328/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

